Kellar Ed, Bornstein Susan M, Caban Aleny, Célingant Catherine, Crouthamel Michelle, Johnson Chrissy, McIntire Patricia A, Milstead Kenneth R, Patterson Jaclyn K, Wilson Brett
1 Development Operations, Data Science. Astellas Pharma Global Development Inc, Northbrook, IL, USA.
2 Clinical Sciences & Operations, Pfizer Inc, Groton, CT, USA.
Ther Innov Regul Sci. 2016 Nov;50(6):682-696. doi: 10.1177/2168479016670689. Epub 2016 Oct 14.
TransCelerate BioPharma has created the eSource Initiative with the intent to facilitate the industry's movement toward optimal usage of electronic data sources. Although guidance and standards have been in place for some time, data collection methods and technology have not been utilized to their fullest capability, and transcription between electronic systems continues to be the norm.
The TransCelerate approach for the eSource Initiative is to understand the current landscape and highlight factors that are influencing the adoption of new technologies. As a preliminary step in this process, TransCelerate surveyed member companies regarding eSource usage and barriers.
Literature review, stakeholder engagement, and the member survey have provided insight into the current landscape, which will help TransCelerate to develop proposals for best practices for industry utilization of electronic data collection tools and methods to benefit all stakeholders.
Based on survey results, companies generally have taken steps to leverage current eSource technologies and prepare for optimal utilization of electronic data sources. The TransCelerate eSource Initiative will continue to evaluate the technology, regulatory, standards, and health care landscape to support the goal of improving global clinical science and global clinical trial execution. Forthcoming publications will focus on technology landscape, future vision, and demonstration projects.
跨速生物制药公司发起了电子源倡议,旨在推动行业朝着优化使用电子数据源的方向发展。尽管相关指南和标准已经出台了一段时间,但数据收集方法和技术尚未得到充分利用,电子系统之间的转录仍然是常态。
跨速生物制药公司开展电子源倡议的方法是了解当前形势,并突出影响新技术采用的因素。作为这一过程的初步步骤,跨速生物制药公司就电子源的使用情况和障碍对成员公司进行了调查。
文献综述、利益相关者参与以及成员调查提供了对当前形势的洞察,这将有助于跨速生物制药公司制定关于行业利用电子数据收集工具和方法的最佳实践建议,以使所有利益相关者受益。
根据调查结果,各公司普遍已采取措施利用当前的电子源技术,并为最佳利用电子数据源做好准备。跨速生物制药公司的电子源倡议将继续评估技术、监管、标准和医疗保健形势,以支持改善全球临床科学和全球临床试验执行情况的目标。即将发表的文章将聚焦技术形势、未来愿景和示范项目。